Tumor News and Research

RSS

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

Chromatin accessibility as an early marker of severe COVID-19

A new study explores the possible use of chromatin remodeling in predicting a severe clinical trajectory for COVID-19.

11 Apr 2022

New instrument will help Columbia scientists to study heavy ion radiation therapy

Heavy ions could radically improve radiation therapy for treatment of pancreatic cancer and other difficult-to-treat tumors if researchers can better understand how the ions work against cancer.

11 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

Researchers assess the impact of interval administration of LD-IL-2 was examined in 18 T1D patients who received a three-day dosing interval.

10 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Novel therapy advances to clinical trial for the treatment of glioblastoma

A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.

10 Apr 2022

Simple interventions reduced radiation exposure to the heart during lung cancer treatment

Radiation to the heart during treatment for locally advanced lung cancer is associated with an increased risk of major adverse cardiac events within the first two years following treatment. The higher the cardiac dose exposure, the higher the risk of a cardiac event.

8 Apr 2022

New delivery method enhances the "attack power" of CAR T cells against tumors

One cutting-edge cancer treatment exciting researchers today involves collecting and reprogramming a patient's T cells – a special set of immune cells – then putting them back into the body ready to detect and destroy cancerous cells.

8 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

Substantial SARS-CoV-2 infection in perivascular cells of inflamed blood vessels

A new study demonstrated that vascular inflammation leads to heightened SARS-CoV-2 infection in perivascular cells.

8 Apr 2022

Nanomedicine for treating life-threatening brain tumors

Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka) has announced that Dr. Sabina Quader et al. published a review article focusing on the recent nanomedicines for brain cancers on Advanced Drug Delivery Review in this March.

8 Apr 2022

UC researcher awarded renewal grant to continue the study of genetic drivers of breast cancer

A grant renewal for a University of Cincinnati researcher will help continue the study of genetic drivers of breast cancer and potential therapeutic targets.

7 Apr 2022

New ML models show high accuracy in predicting complications after abdominal hernia repair

Machine learning (ML) models developed by surgeons at the University of Texas MD Anderson Cancer Center in Houston have shown a high level of accuracy in predicting which types of patients are most likely to have a hernia recurrence or other complications.

7 Apr 2022

Tumor News and Research

Nanocell COVID-19 vaccine elicits potent neutralizing response

Chromatin accessibility as an early marker of severe COVID-19

New instrument will help Columbia scientists to study heavy ion radiation therapy

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

Novel therapy advances to clinical trial for the treatment of glioblastoma

Simple interventions reduced radiation exposure to the heart during lung cancer treatment

New delivery method enhances the "attack power" of CAR T cells against tumors

City of Hope's late-breaking clinical trial data to be presented at AACR

Substantial SARS-CoV-2 infection in perivascular cells of inflamed blood vessels

Nanomedicine for treating life-threatening brain tumors

UC researcher awarded renewal grant to continue the study of genetic drivers of breast cancer

New ML models show high accuracy in predicting complications after abdominal hernia repair

Study investigates biochemical, biophysical, and immunological profile of COVID-19 respiratory secretions

Creation of immunosuppressive environment is key to the progression of colorectal cancer development

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News